
Lung cancer stands as one of the deadliest forms of cancer, with someone succumbing to it worldwide every 30 seconds. The current 5-year survival rate for lung cancer patients averages only 17% for men and 24% for women. Despite smoking being a significant contributor to lung cancer, it also affects non-smokers. Consequently, project collaborators will focus on identifying all potential risk factors and innovating new diagnostic, preventive, and treatment methods.
The overarching objective of the LUCIA project is to enhance early diagnosis, prevention, and treatment of lung cancer, with a particular emphasis on rarer types of the disease. The project's research endeavors will lead to recommendations for an early diagnosis program and effective lung cancer prevention strategies.
The LUCIA project is overseen by the Technion Institute of Technology in Israel, with implementation taking place in Latvia under the leadership of the Institute of Clinical and Preventive Medicine at the Lithuanian University of Technology. The project is further supported by the chief specialist in pneumology at the Riga Eastern Clinical University Hospital, Professor Alvila Kram, who provides scientific guidance.
For those unable to attend in person, the event will be livestreamed at the following link.
This project has received funding from the European Union’s research and innovation programme Horizon Europe under grant agreement No 101096473.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.